CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been ...

MILWAUKEE, Oct. 30, 2025 /PRNewswire/ -- The Society for Immunotherapy of Cancer (SITC) received an incredible number of abstract submissions in 2025, more than 1,300, including many clinical based ...

Nonsteroidal Anti-Inflammatory Drugs, Alone or Combined With Opioids, for Cancer Pain Brief description of the intervention, explicit identification of the primary end point, and presentation of ...

Real-world data from 844,000 patient records highlight the power of remote therapeutic monitoring to improve outcomes and reduce risk in chronic pain care The abstract presents a retrospective cohort ...

Conference abstracts explored the relationship between serum phosphate levels on mortality in patients with chronic kidney disease (CKD) and cost burdens for employers as patients transition to ...

PENNINGTON, N.J. and SAN DIEGO, May 21, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (the "Company" or "OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer ...

These clinical abstracts are courtesy of the organization WeMove (Worldwide Education and Awareness for Movement Disorders). Learn more about this group at their Web site: www.wemove.org. WeMove ...

AFM24-101 phase 1/2 results in 10 patients from the non-small cell lung cancer (NSCLC) cohort demonstrated clinical activity and a well-managed safety profile in heavily pretreated patients with EGFR ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--H3 Biomedicine Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the presentation of four posters ...

AFM24-101 phase 1/2 interim results from the non-small cell lung cancer cohort accepted for poster presentation AFM24-101 phase1/2 interim results from the colorectal cancer cohort accepted for online ...